دورية أكاديمية
[New pharmaceuticals in cardiology. Heart failure, anticoagulation, dyslipidemia].
| العنوان: | [New pharmaceuticals in cardiology. Heart failure, anticoagulation, dyslipidemia]. |
|---|---|
| عنوان ترانسليتريتد: | Neue Medikamente in der Kardiologie. Herzinsuffizienz, Antikoagulation, Dyslipidämien. |
| المؤلفون: | Czepluch FS; Klinik für Kardiologie und Pneumologie, Herzzentrum, Universitätsmedizin Göttingen, Georg-August-Universität, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland., Hasenfuß G, Jacobshagen C |
| المصدر: | Der Internist [Internist (Berl)] 2014 Apr; Vol. 55 (4), pp. 382-9. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | German |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0264620 Publication Model: Print Cited Medium: Internet ISSN: 1432-1289 (Electronic) Linking ISSN: 00209554 NLM ISO Abbreviation: Internist (Berl) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin, New York, Springer-Verlag. |
| مواضيع طبية MeSH: | Drug Approval*, Cardiovascular Agents/*therapeutic use , Cardiovascular Diseases/*drug therapy , Drugs, Investigational/*therapeutic use, Antibodies, Monoclonal/therapeutic use ; Atrial Fibrillation/complications ; Cardiovascular Diseases/mortality ; Cholesterol, LDL/blood ; Clinical Trials, Phase III as Topic ; Cyclophosphamide/therapeutic use ; Female ; Heart Failure/drug therapy ; Humans ; Hypercholesterolemia/drug therapy ; Pregnancy ; Proprotein Convertase 9 ; Proprotein Convertases/antagonists & inhibitors ; Recombinant Proteins/therapeutic use ; Relaxin/therapeutic use ; Serine Endopeptidases ; Stroke/prevention & control ; Venous Thromboembolism/drug therapy |
| مستخلص: | Three innovative pharmaceuticals which might play an important role in the field of cardiology in the near future were recently tested in large clinical studies. Serelaxin, a vasoactive hormone peptide that is produced during pregnancy, reduces vessel resistance, increases cardiac output, and improves renal function. Lately, it was demonstrated that serelaxin significantly reduces congestion symptoms in patients with acute heart failure. As a secondary endpoint the mortality at day 180 was reduced. Therefore, serelaxin seems to be a promising new drug for the treatment of acute heart failure which might have a prognostic impact. Edoxaban is a selective factor Xa inhibitor, which inhibits thrombin production and thrombus formation. Two recently published studies reported that edoxaban is at least as effective as the vitamin K antagonist warfarin in prevention and treatment of venous thromboembolism and in the prevention of stroke and systemic embolism due to nonvalvular atrial fibrillation. Compared to warfarin, edoxaban significantly exhibited less frequent severe bleeding complications. Edoxaban will probably soon be the fourth new oral anticoagulant available for patients. The serine protease proprotein convertase subtilisin/kexin 9 (PCSK9) reduces the ability of the liver to bind low-density lipoprotein cholesterol (LDL-C) and to remove it from the circulation. Recently, a monoclonal antibody for PCSK9 was developed which induces a LDL-C plasma level reduction up to 73 % and also decreases lipoprotein(a) and apolipoprotein B. PCSK9 inhibition is a promising new mechanism for LDL-C reduction and the corresponding drug will be presumably approved soon by the regulatory authorities. |
| References: | Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42. (PMID: 23784266) Thromb Haemost. 2012 May;107(5):925-36. (PMID: 22398655) Curr Heart Fail Rep. 2013 Sep;10(3):198-203. (PMID: 23836112) J Card Fail. 2009 Apr;15(3):182-90. (PMID: 19327619) Drugs. 2011 Aug 20;71(12):1503-26. (PMID: 21861537) Lancet. 2013 Jan 5;381(9860):29-39. (PMID: 23141816) Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. (PMID: 24319220) N Engl J Med. 2012 Nov 15;367(20):1891-900. (PMID: 23113833) J Biol Chem. 2007 Jun 22;282(25):18602-18612. (PMID: 17452316) Curr Heart Fail Rep. 2010 Jun;7(2):75-82. (PMID: 20424993) Eur Heart J. 2014 Feb;35(7):431-41. (PMID: 24255129) Lancet. 2010 Nov 13;376(9753):1670-81. (PMID: 21067804) Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5374-9. (PMID: 15805190) Curr Opin Lipidol. 2013 Dec;24(6):510-7. (PMID: 24184943) N Engl J Med. 2006 Mar 23;354(12):1264-72. (PMID: 16554528) Nat Genet. 2003 Jun;34(2):154-6. (PMID: 12730697) Vasc Health Risk Manag. 2013;9:593-8. (PMID: 24124376) N Engl J Med. 2013 Oct 10;369(15):1406-15. (PMID: 23991658) J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. (PMID: 23973703) N Engl J Med. 2012 Mar 22;366(12):1108-18. (PMID: 22435370) J Am Coll Cardiol. 2013 Jan 15;61(2):196-206. (PMID: 23273292) Lancet. 2009 Apr 25;373(9673):1429-39. (PMID: 19329178) Lancet. 2012 Dec 8;380(9858):2007-17. (PMID: 23141813) Herz. 2013 Dec;38(8):812-20. (PMID: 24146139) N Engl J Med. 2013 Nov 28;369(22):2093-104. (PMID: 24251359) Eur Heart J. 2014 Apr;35(16):1041-50. (PMID: 24316514) Heart Fail Rev. 2009 Dec;14(4):321-9. (PMID: 19101795) |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Cardiovascular Agents) 0 (Cholesterol, LDL) 0 (Drugs, Investigational) 0 (Recombinant Proteins) 0 (serelaxin protein, human) 8N3DW7272P (Cyclophosphamide) 9002-69-1 (Relaxin) EC 3.4.21.- (PCSK9 protein, human) EC 3.4.21.- (Proprotein Convertase 9) EC 3.4.21.- (Proprotein Convertases) EC 3.4.21.- (Serine Endopeptidases) |
| تواريخ الأحداث: | Date Created: 20140313 Date Completed: 20141121 Latest Revision: 20211021 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1007/s00108-013-3418-1 |
| PMID: | 24619100 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-1289 |
|---|---|
| DOI: | 10.1007/s00108-013-3418-1 |